← All comparisons

AOD-9604 vs HGH Fragment 176-191

Last updated

The key difference

AOD-9604 is a modified version of the hGH fragment 176-191, the part of growth hormone associated with fat breakdown, with an added amino acid at one end. Both were studied for fat loss; AOD-9604's clinical trials did not show meaningful weight loss.

Side by side

What it is
AOD-9604A modified fragment of the C-terminus of human growth hormone (residues 176-191) studied for fat-loss effects without the broader growth-promoting actions of full GH.
HGH Fragment 176-191HGH Fragment 176-191 is the C-terminal fragment of human growth hormone studied primarily for its fat-reducing effects without the broader growth-promoting actions of full-length GH. It is a popular research compound for lipolysis.
Research status
AOD-9604Research chemical
HGH Fragment 176-191Research chemical
Category
AOD-9604Weight & Metabolic
HGH Fragment 176-191Weight & Metabolic
Half-life
AOD-9604Approximately 30 minutes
HGH Fragment 176-191Short; on the order of 20 to 30 minutes
Routes
AOD-9604subcutaneous
HGH Fragment 176-191subcutaneous
Reported dosing
AOD-9604Research literature references ~250-500 mcg daily, often dosed in the morning on an empty stomach. Educational range only, not advice.
HGH Fragment 176-191Research-use only, not medical advice. The research literature commonly references subcutaneous amounts around 250 to 500 mcg per administration, sometimes split before fasted activity, with weight-based scaling in animal studies.
Studied for
AOD-9604
  • Promotes lipolysis (fat breakdown) without raising IGF-1
  • Does not appear to impair glucose tolerance
  • No significant effect on growth or organ size
  • Studied for cartilage and joint support
HGH Fragment 176-191
  • Stimulates lipolysis and fat breakdown in research models
  • Inhibits new fat formation (lipogenesis)
  • Does not appreciably raise IGF-1 levels
  • Reported minimal effect on blood glucose compared with full GH
Side effects
AOD-9604
  • Generally mild; injection-site reactions
  • Occasional headache
  • Limited evidence of strong fat-loss efficacy in humans
  • Long-term safety data is limited
HGH Fragment 176-191
  • Injection-site redness or irritation
  • Transient flushing or headache
  • Possible fatigue or lethargy
  • Limited long-term human safety data
Cited studies
AOD-96044 on its page
HGH Fragment 176-1914 on its page

How AOD-9604 works

AOD-9604 is a synthetic peptide based on the lipolytic C-terminal fragment (176-191) of human growth hormone. It is thought to stimulate lipolysis and inhibit lipogenesis by acting on beta-3 adrenergic receptors in adipose tissue, mimicking GH's fat-burning effects without raising IGF-1 or affecting blood glucose. This separation of the metabolic action from the growth-promoting action is the basis of its research interest.

Full AOD-9604 profile →

How HGH Fragment 176-191 works

The fragment corresponds to amino acids 176 to 191 of human growth hormone, the region associated with GH's lipolytic activity. In animal models it stimulates lipolysis (fat breakdown) and inhibits lipogenesis, apparently by acting on adipose tissue beta-3 adrenergic signaling and modulating fatty acid metabolism. Because it lacks the residues responsible for GH's effects on growth and insulin resistance, it is reported not to meaningfully raise IGF-1 or blood glucose.

Full HGH Fragment 176-191 profile →

Dosing shown is what research and community sources report, not a recommendation. For educational and research purposes only; not medical advice. How we source this

PeptideChat is for educational and research purposes only. Nothing on this site constitutes medical advice. Peptides are sold as research chemicals only and are not intended for human use. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. PeptideChat is an independent educational resource — not a pharmacy, compounding, or 503A/503B outsourcing facility — and does not sell products or provide medical advice.